Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Taxes: 2018-2025

Historic Current Taxes for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $1.0 million.

  • China SXT Pharmaceuticals' Current Taxes fell 5.17% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 5.17%. This contributed to the annual value of $1.0 million for FY2025, which is 2.00% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Current Taxes stood at $1.0 million for FY2025, which was down 2.00% from $1.1 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Current Taxes ranged from a high of $1.2 million in FY2022 and a low of $1.0 million during FY2025.
  • Its 3-year average for Current Taxes is $1.1 million, with a median of $1.1 million in 2024.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Current Taxes increased by 17.67% in 2021, and later declined by 5.38% in 2023.
  • Yearly analysis of 5 years shows China SXT Pharmaceuticals' Current Taxes stood at $1.2 million in 2021, then climbed by 0.56% to $1.2 million in 2022, then fell by 5.38% to $1.1 million in 2023, then declined by 4.74% to $1.1 million in 2024, then dropped by 2.00% to $1.0 million in 2025.